JP2005521671A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521671A5
JP2005521671A5 JP2003564046A JP2003564046A JP2005521671A5 JP 2005521671 A5 JP2005521671 A5 JP 2005521671A5 JP 2003564046 A JP2003564046 A JP 2003564046A JP 2003564046 A JP2003564046 A JP 2003564046A JP 2005521671 A5 JP2005521671 A5 JP 2005521671A5
Authority
JP
Japan
Prior art keywords
disorder
diabetes
compound according
triaza
fluorene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003564046A
Other languages
English (en)
Japanese (ja)
Other versions
JP4213042B2 (ja
JP2005521671A (ja
Filing date
Publication date
Priority claimed from GBGB0202015.4A external-priority patent/GB0202015D0/en
Application filed filed Critical
Publication of JP2005521671A publication Critical patent/JP2005521671A/ja
Publication of JP2005521671A5 publication Critical patent/JP2005521671A5/ja
Application granted granted Critical
Publication of JP4213042B2 publication Critical patent/JP4213042B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003564046A 2002-01-29 2003-01-17 アザ−アリールピペラジン Expired - Fee Related JP4213042B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives
PCT/EP2003/000459 WO2003064423A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines

Publications (3)

Publication Number Publication Date
JP2005521671A JP2005521671A (ja) 2005-07-21
JP2005521671A5 true JP2005521671A5 (enExample) 2005-12-22
JP4213042B2 JP4213042B2 (ja) 2009-01-21

Family

ID=9929954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564046A Expired - Fee Related JP4213042B2 (ja) 2002-01-29 2003-01-17 アザ−アリールピペラジン

Country Status (33)

Country Link
US (1) US7098337B2 (enExample)
EP (1) EP1472255B1 (enExample)
JP (1) JP4213042B2 (enExample)
KR (1) KR100644004B1 (enExample)
CN (1) CN1290847C (enExample)
AR (1) AR038237A1 (enExample)
AT (1) ATE318817T1 (enExample)
AU (1) AU2003205622B2 (enExample)
BR (1) BR0307291A (enExample)
CA (1) CA2472954C (enExample)
DE (1) DE60303791T2 (enExample)
DK (1) DK1472255T3 (enExample)
EA (1) EA200400881A1 (enExample)
EC (1) ECSP045208A (enExample)
ES (1) ES2259757T3 (enExample)
GB (1) GB0202015D0 (enExample)
GT (1) GT200300015A (enExample)
HR (1) HRP20040653A2 (enExample)
IL (1) IL162727A0 (enExample)
MA (1) MA27097A1 (enExample)
MX (1) MXPA04007147A (enExample)
NO (1) NO20043547L (enExample)
PA (1) PA8564001A1 (enExample)
PE (1) PE20030847A1 (enExample)
PL (1) PL371922A1 (enExample)
PT (1) PT1472255E (enExample)
RS (1) RS65704A (enExample)
SI (1) SI1472255T1 (enExample)
TN (1) TNSN04136A1 (enExample)
TW (1) TW200307683A (enExample)
UY (1) UY27627A1 (enExample)
WO (1) WO2003064423A1 (enExample)
ZA (1) ZA200405458B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1636224B1 (en) * 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN1867332A (zh) * 2003-10-24 2006-11-22 索尔瓦药物有限公司 包含选择性cb1-拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗
AR046132A1 (es) * 2003-10-24 2005-11-23 Solvay Pharm Gmbh Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
CA2609634C (en) * 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
US7622466B2 (en) * 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CA2870019C (en) * 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
CA2880682A1 (en) * 2012-08-06 2014-02-13 F. Hoffmann-La Roche Ag Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3033142A1 (en) * 2016-08-19 2018-02-22 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Similar Documents

Publication Publication Date Title
JP2004517852A5 (enExample)
TWI252105B (en) 5HT2C receptor modulators
JP2007516941A5 (enExample)
JP2004519438A5 (enExample)
JP2008524262A5 (enExample)
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
RU2007139255A (ru) Новые оксадиазольные производные и их медицинское применение
JP2010523654A (ja) 複素環化合物およびその使用方法
TW200821293A (en) Tartrate salt of(7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6, 7-dihydro-5H-cyclopenta[b]pyridine
JP2017524005A5 (enExample)
JP2009538867A5 (enExample)
JP2019532079A5 (enExample)
JP2014526435A5 (enExample)
HRP20090640T1 (hr) Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida
RU2018130727A (ru) Органические соединения
JP2010514832A5 (enExample)
JP2002523491A5 (enExample)
JP2008513498A5 (enExample)
JP2010538001A5 (enExample)
JP2002523508A5 (enExample)
RU2008139481A (ru) Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение
JP2020503246A5 (enExample)
JP2009538866A5 (enExample)
JP2007508360A5 (enExample)
JP2015531764A5 (enExample)